Skip to main content
Premium Trial:

Request an Annual Quote

Molzym Gets CE Mark for Sepsis PCR Test

NEW YORK (GenomeWeb News) – German firm Molzym has received the CE Mark for its PCR-based test for sepsis enabling the firm to market the test throughout the European Union.
 
Molzym’s SepsiTest detects more than 345 relevant sepsis pathogens and can provide results in less than four hours. The firm claims that it is the first PCR-based assay that can detect all of the relevant strains in one test.
 
“Broad-spectrum molecular sepsis diagnostics will for the first time enable early targeted treatments and SepsiTest will greatly support clinicians in their bedside decision-making,” Michael Lorenz, chief scientist at Bremen, Germany-based Molzym, said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.